Pharma Mar (PHM.MC) traded down -2.05 % during a 24 hours period ending at 10:09 PM Central Europe on Tuesday 27th. One Pharma Mar stock can currently be bought for about EUR 69.1 on popular exchanges. Current supply of Pharma Mar stocks is 17.3 mn. Pharma Mar has a current market capitalization of EUR 1.2 bn and approximately EUR 1.2 mn worth of Pharma Mar was traded on exchanges in the last 24 hours. Since last month end, Pharma Mar has traded -5.78 % down. Simple moving average of last 200 days is at EUR 82.27. The highest price of past 52 weeks was recorded at EUR 105.2 on 05/07/2026. 52 weeks low was at EUR 64 on 06/12/2026.

Here is how related stocks have performed in the past 24 hours:

  • Aedas Homes (AEDAS.MC) traded down -2.92 % and now trades at EUR 22.2. Current market capitalisation for Aedas Homes is EUR 937.1 mn. Aedas Homes has a current price to earnings ratio of 15.99.

  • Clinica Baviera (CBAV.MC) traded down -0.74 % and now trades at EUR 53.6. Current market capitalisation for Clinica Baviera is EUR 862.5 mn. Clinica Baviera has a current price to earnings ratio of 18.92.

  • Montepino Logistica Sl (MLMTP.PA) traded flat 0 % and now trades at EUR 10. Montepino Logistica Sl has a market capitalisation of EUR 859.9 mn. Montepino Logistica Sl has a current price to earnings ratio of 10.41.

  • Atresmedia De Medios De (A3M.MC) traded up 0.34 % and now trades at EUR 5.83. Current market capitalisation for Atresmedia De Medios De is EUR 1.3 bn. Current price/earnings ratio for Atresmedia De Medios De is 24.15.

  • Prosegur Cash (CASH.MC) traded up 0.3 % and now trades at EUR 0.66. Prosegur Cash has a market capitalisation of EUR 990.1 mn. Prosegur Cash has a current price to earnings ratio of 10.83.

About Pharma Mar

Pharma Mar SA is a biopharmaceutical company based in Madrid, Spain, that specializes in discovering and developing marine-derived anticancer drugs both nationally and internationally. The company operates through two segments: Biopharmaceuticals and Consumer Chemicals. Their main product is Yondelis, an antitumor agent used for the treatment of advanced soft tissue sarcomas and relapsed ovarian cancer. Additionally, they develop clinical-stage programs, including Aplidin, Lurbinectedin, PM184, and PM14. Pharma Mar SA also provides diagnostics kits for genetic diagnostics and DNA analysis; and produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. The company was founded in 1986. Their website is www.pharmamar.com , and they are listed on the Bolsa De Madrid stock exchange.